# Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP

> **NCT06168734** · PHASE3 · WITHDRAWN · sponsor: **Venatorx Pharmaceuticals, Inc.**

## Conditions studied

- Ventilator-associated Pneumonia
- Hospital-acquired Pneumonia

## Interventions

- **DRUG:** Cefepime-taniborbactam
- **DRUG:** Meropenem

## Key facts

- **NCT ID:** NCT06168734
- **Lead sponsor:** Venatorx Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-06
- **Primary completion:** 2027-06
- **Final completion:** 2027-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study suspended
- **Last updated:** 2025-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06168734

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06168734, "Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06168734. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*